Vanda Pharmaceuticals Inc. (VNDA) Receives $33.67 Consensus Target Price from Brokerages
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has been assigned an average rating of “Hold” from the thirteen analysts that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $33.67.
A number of equities analysts have issued reports on the stock. ValuEngine cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 18th. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 18th. Finally, BidaskClub cut shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, April 11th.
In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos sold 72,872 shares of the firm’s stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $15.34, for a total value of $1,117,856.48. Following the sale, the chief executive officer now owns 1,276,343 shares in the company, valued at $19,579,101.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 8.20% of the stock is currently owned by company insiders.
NASDAQ VNDA traded up $0.45 during trading hours on Monday, reaching $15.13. The company’s stock had a trading volume of 569,300 shares, compared to its average volume of 822,738. Vanda Pharmaceuticals has a 52 week low of $13.66 and a 52 week high of $33.44. The stock has a market capitalization of $777.51 million, a P/E ratio of 31.52 and a beta of 0.59.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.08). Vanda Pharmaceuticals had a return on equity of 8.07% and a net margin of 10.92%. The business had revenue of $47.71 million during the quarter, compared to the consensus estimate of $51.74 million. During the same period in the prior year, the business earned $0.14 EPS. The business’s revenue was up 9.5% on a year-over-year basis. On average, research analysts anticipate that Vanda Pharmaceuticals will post 0.06 earnings per share for the current year.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Featured Article: Why investors pay attention to retained earnings
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.